clinical trial · NCT02773355
Timely Detection of Treatment Emergent Serious and Non-serious Adverse Events for Saxenda® in Mexican Patients
Novo Nordisk A/S·—·completed·n = 27
Obesityliraglutide 3.0 mg
brief summary
This trial is conducted in North America. The aim is to investigate timely detection of pancreatitis cases as well as cases of suspicion of serious and non-serious adverse reactions possibly or probably related to Saxenda® in Mexican patients.
started
May 16, 2016
primary completion
Nov 30, 2021
completion
Feb 28, 2022
last updated
Apr 13, 2026
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol